The Fund is a passively managed exchange traded Fund that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index), subject to the deduction of the ongoing charges and other costs associated with operating the Fund. The index is comprised of bio-technology companies which are publically traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An orphan drug is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders.